Effects of antimetabolites on adenovirus replication in sensitive and resistant human melanoma cell lines.
Methotrexate (MTX), 6-thioguanine (6-TG) and cytosine arabinoside (ara-C) inhibited the replication of adenovirus (viral capacity) more in drug-sensitive than in resistant human melanoma cell lines. By comparison, inhibition of cellular DNA and RNA synthesis after short treatment periods (less than 48 hr) was not a good predictor of cellular sensitivity. MTX, an inhibitor of de novo nucleotide synthesis, was most effective when added to cells just before infection with virus and inhibited viral capacity at doses 10-1000-fold lower than those required to affect cell survival. The MTX-sensitive cell lines, members of a DNA repair deficient group sensitive also to killing by methylating agents (the Mer- phenotype), were not deficient in dihydrofolate reductase but exhibited DNA fragmentation after treatment with MTX for 48 hr. 6-TG and ara-C, inhibitors of purine and pyrimidine salvage, were most inhibitory to viral capacity when added greater than 36 hr before virus infection and were less effective than MTX (doses 5-7-fold and 4-24-fold higher than for cell survival respectively). No correlation was found between MTX sensitivity and sensitivity to 6-TG or ara-C. These results indicate that (i) inhibition of viral capacity is a more comprehensive test of antimetabolite cytotoxicity than inhibition of cellular DNA or RNA synthesis; (ii) the viral capacity assay correctly predicts cellular sensitivity to MTX, 6-TG and ara-C and therefore has potential for application to primary cultures of human tumours; and (iii) MTX-sensitive cell lines and adenovirus replication rely heavily on de novo nucleotide synthesis, which in Mer- cells appears to be linked to a DNA repair defect as yet undefined.
Queensland Institute of Medical Research, Herston, Australia.
P
P
Musk
A
A
Stowers
P G
PG
Parsons
D000256:Adenoviridae / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology* / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D004351:Drug Resistance; D006801:Humans; D007700:Kinetics; D008545:Melanoma / Q000188:drug therapy* / Q000382:microbiology; D008727:Methotrexate / Q000494:pharmacology* / Q000627:therapeutic use; D012313:RNA / Q000096:biosynthesis; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism; D013866:Thioguanine / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014779:Virus Replication / Q000187:drug effects*
D003561:Cytarabine; D012313:RNA; D004247:DNA; D013762:Tetrahydrofolate Dehydrogenase; D013866:Thioguanine; D008727:Methotrexate